Recorlev (Levoketoconazole) Patent Expiration, LOE Window & CMS Spending

Recorlev (Levoketoconazole) by Strongbridge Dublin: FDA Orange Book LOE 2040-03-02, 0 AB generics, $39.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorStrongbridge Dublin
FDA Application & PathwayN214133 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-03-02
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$39.8M
2024 Medicare Part D Spend$29.7M
2024 Medicaid Spend$10.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 38.7% 2-yr change)